A study conducted by Szliszka, Helewski, Mizgala, and Krol (2011) investigated that fisetin treatment in prostate cancer cell lines (LNCaP, DU145, and PC3) sensitized the tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐resistant HepG2 cell. This evidence concerns the gene TNFSF10 and prostate carcinoma.